Tablets and Capsules

Rosuvas F 20 Tab

Availablity: In stock

1 Strip(s) (10 Tablet each). This product is Manufactured by Ranbaxy Laboratories Ltd

₹ 295.00

Composition: Rosuvastatin 20mg + Finofibrate 160mg


  • Rosuvastatin is a member of the drug class of statins, lowering high cholesterol and triglycerides in certain patients. It is recommended to be used only after other measures such as diet and exercise.

Typical uses:

  • It is used to slow atherosclerosis (narrowing of the arteries) in patients with high blood cholesterol levels.
  • It is also used in certain patients to reduce the risk of heart attack or stroke.

Mechanism of action:

  • It acts by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.


  • If one allergic to any ingredient in Rosuvastatin.
  • In pregnancy and breast feeding.
  • In active liver disease or abnormal liver function.
  • If one addicted to alcohol or a history of alcohol abuse.

Adverse effect:

  •  More serious side effect are muscle pain, tenderness, lack of energy, fever, chest pain, jaundice, dark colored, or foamy urine, pain in the upper right part of the abdomen, loss of appetite, flu-like symptoms, sore throat, chills.

Drug interaction:

Rosuvastatin may have negative interaction with following drugs:

  • Warfarin (anticoagulant), cimetidine, cyclosporine, ketoconazole, clofibrate, fenofibrate, gemfibrozil, spironolactone and niacin.
  • It may also interact with antiviral drugs like atazanavir, lopinavir and ritonavir.
  • Alcohol intake while on rosuvastatin may increase risk of liver damage.
  • Antacids should not be taken within two hours of taking rosuvastatin.



  • Fenofibrate is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease.

Typical uses: 

  • It is used alone or along with statins in the treatment of hypercholesterolemia, dyslipidemia and hypertriglyceridemia.

Mechanism of action:

  • It acts by activating Peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII, which increases lipolysis and elimination of triglyceride-rich particles from plasma.


Fenofibrate is contraindicated in the following events:

  • Renal failure
  • Liver disease
  • Gall bladder disease

Adverse effects:

The most common adverse effects are:

  • Headache, back pain, nasopharyngitis, myalgia, Joint pain or arthralgia, upper respiratory tract infection
  • Myopathy and rhabdomyolysis, when co-adminstered with statins.

Drug interaction:

  • Combination of statins and fenofibrate may increase the risk of rhabdomyolysis or myopathy
  • It may increase the risk of bleeding when administered with anticoagulants.

Schedule: H

Product Specifications